CNS pharmacokinetics of antifungal agents
- 1 August 2007
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 3 (4), 573-581
- https://doi.org/10.1517/17425225.3.4.573
Abstract
The goal in treatment of infections is to achieve a beneficial effect while minimizing toxicity. It is widely recognized that the principles of pharmacokinetics and pharmacodynamics are critical to determining an adequate dose–response relationship. There has been an increased involvement of the CNS to infection from opportunistic and endemic fungi over the last several decades due to establishment of solid-organ and bone marrow transplantation as well as immunosuppression from HIV. In this regard it has become critical to define optimal dosing regimens by an understanding of the processes which govern delivery of an antifungal agent to the targeted CNS site of involvement. The objective of this review is to: i) summarize published experimental and clinical antifungal pharmacokinetics; and ii) examine the relationship between CNS antifungal pharmacokinetics and efficacy. Examination of these studies reveal marked variability among antifungal drugs with regard to cerebrospinal fluid and brain parenchymal penetration. Formal examination of the relationship between CNS antifungal pharmacokinetics and efficacy are limited. The few experimental studies available suggest that brain parenchymal kinetics is a superior predictor of antifungal efficacy than cerebrospinal fluid concentrations.Keywords
This publication has 64 references indexed in Scilit:
- Population Pharmacokinetics of Amphotericin B Lipid Complex in NeonatesAntimicrobial Agents and Chemotherapy, 2005
- Efficacy of Caspofungin against Central Nervous System Aspergillus fumigatus Infection in Mice Determined by TaqMan PCR and CFU MethodsAntimicrobial Agents and Chemotherapy, 2005
- Efficacy of Posaconazole in a Murine Model of Central Nervous System AspergillosisAntimicrobial Agents and Chemotherapy, 2004
- Posaconazole Therapy of Disseminated Phaeohyphomycosis in a Murine ModelAntimicrobial Agents and Chemotherapy, 2004
- Antifungal Therapy for Central Nervous System Histoplasmosis, Using a Newly Developed Intracranial Model of InfectionThe Journal of Infectious Diseases, 2002
- Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical SettingClinical Pharmacokinetics, 2002
- Comparative Efficacy and Distribution of Lipid Formulations of Amphotericin B in ExperimentalCandida albicansInfection of the Central Nervous SystemThe Journal of Infectious Diseases, 2000
- Pharmacokinetic Optimisation of the Treatment of Bacterial Central Nervous System InfectionsClinical Pharmacokinetics, 1998
- Survival improvement in coccidioidal meningitis by high-dose intrathecal amphotericin BArchives of Internal Medicine, 1986
- Antifungal Activity of 5-Fluorocytosine as Measured by Disk Diffusion Susceptibility TestingThe Journal of Infectious Diseases, 1977